Meeting
2022 ASCO Gastrointestinal Cancers Symposium
TALENTACE: A phase III, open-label, randomized study of on-demand transarterial chemoembolization combined with atezolizumab + bevacizumab or on-demand transarterial chemoembolization alone in patients with untreated hepatocellular carcinoma.
Authors
Masatoshi Kudo
Kindai University Faculty of Medicine, Osaka, Japan
Masatoshi Kudo , Yabing Guo , Yongqiang Hua , Ming Zhao , Wenge Xing , Yonghong Zhang , Ruibao Liu , Zhenggang Ren , Shanzhi Gu , Zhengyu Lin , Weifu Lv , Yumeng Wang , Jiahong Dong
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session B: Cancers of the Pancreas, Small Bowel, and Hepatobiliary Tract
Track
Pancreatic Cancer,Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Small Bowel Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04712643
DOI
10.1200/JCO.2022.40.4_suppl.TPS487
Abstract #
TPS487
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
ABC-HCC: A phase IIIb, randomized, multicenter, open-label trial of atezolizumab plus bevacizumab versus transarterial chemoembolization (TACE) in intermediate-stage hepatocellular carcinoma.
First Author: Friedrich Foerster
Poster
2021 ASCO Annual Meeting
REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.
First Author: Kazuomi Ueshima
Poster
2020 ASCO Virtual Scientific Program
Complete responses (CR) in patients receiving atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in IMbrave150: A phase III clinical trial for unresectable hepatocellular carcinoma (HCC).
First Author: Richard S. Finn
Poster
2023 ASCO Annual Meeting
Primary analysis of a phase II study of atezolizumab plus bevacizumab for TACE-unsuitable patients with tumor burden beyond up-to-seven criteria in intermediate-stage hepatocellular carcinoma: REPLACEMENT study.
First Author: Kazuomi Ueshima